Concepedia

Albiruni Abdul Razak

AA

5

Publications

204

Citations

5

H-Index

2020

Active since

Affiliations

Princess Margaret Cancer Centre(Current)

Dana-Farber Cancer Institute

WinnMed

Hospital Universitario Fundación Jiménez Díaz

Leiden University Medical Center

Albiruni Abdul Razak is an author at Princess Margaret Cancer Centre specializing in cancer research, molecular diagnostics, and engineering.

Top concepts

Publications per year

2020–2024

5

Publications

5

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sebastian Bauer, Robin L. Jones, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2022 · 104 citations · Full text

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Mrinal M. Gounder, Albiruni Abdul Razak, Neeta Somaiah et al. · Journal of Clinical Oncology · 2022 · 37 citations · Full text

537MO First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers

María Vieito, Anna Spreafico, Víctor Moreno et al. · Annals of Oncology · 2020 · 31 citations

, , +9

CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib

Hans Gelderblom, Albiruni Abdul Razak, Matthew H. Taylor et al. · Clinical Cancer Research · 2024 · 22 citations · Full text

Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

Hans Gelderblom, Robin L. Jones, Jean‐Yves Blay et al. · European Journal of Cancer · 2023 · 10 citations · Full text

Rows per page

1–5 of 5